OncoMed Pharma (OMED) Commences Common Stock Offering
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED) announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by OncoMed. In addition, OncoMed intends to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
OncoMed expects to use its existing cash, cash equivalents and short-term investments and the net proceeds from the offering for general corporate purposes, which may include, among other things, increasing its working capital, funding research and development, including its wholly-owned GITRL-Fc immuno-oncology program, and capital expenditures.
Leerink Partners LLC is acting as sole book-running manager for the proposed offering.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 22, 2015. The offering is being made only by means of a prospectus supplement filed today with the SEC. Copies of the preliminary prospectus supplement relating to this offering may be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at email@example.com, or by telephone at (800) 808-7525, ext. 6142.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corvex Management Cuts Signet Jewelers (SIG) Stake in Half
- GoDaddy (GDDY) to Acquire Host Europe Group in ~$1.8B Deal
- Recro Pharma (REPH) Enters Revised Milestone Payment Agreement with Alkermes (ALKS)
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!